F S&P 500
5,061.50 -5.50 (-0.11%) F Dow Jones
38,002.00 +9.00 (+0.02%) F Nasdaq
17,516.00 -55.25 (-0.31%) E-mini Russell 2000 Index Futur
1,985.10 -0.50 (-0.03%) Petróleo
81.12 -0.81 (-0.99%) Oro
2,298.20 -4.70 (-0.20%)
Gossamer Bio, Inc. (GOSS)
Fuera de horario:
Gossamer Bio, Inc.
3013 Science Park Road
Suite 200
San Diego, CA 92121
United States
858 684 1300
https://www.gossamerbio.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 135
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Faheem Hasnain | Co-Founder, CEO, President & Chairman | 910.26k | N/D | 1958 |
| Mr. Bryan Giraudo | COO & CFO | 708.09k | N/D | 1975 |
| Mr. Robert P. Smith | Chief Commercial Officer | 135.79k | N/D | 1969 |
| Mr. Christian Waage | Executive Vice President of Technical Operations & Administration | 583.16k | N/D | 1967 |
| Mr. Jeff Boerneke | General Counsel & Secretary | N/D | N/D | N/D |
| Ms. Deanna Weber | Senior Vice President of Human Resources | N/D | N/D | N/D |
| Dr. Richard Aranda M.D. | Chief Medical Officer | 625.24k | N/D | 1961 |
| Mr. Mario Orlando | Senior Vice President of Commercial New Product Planning | N/D | N/D | N/D |
| Ms. Caryn L. Peterson | Executive Vice President of Regulatory Affairs | N/D | N/D | 1959 |
| Mr. Matt Cravets | Senior Vice President of Biometrics | N/D | N/D | N/D |
Descripción
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
Gestión corporativa
La calificación ISS Governance QuickScore de Gossamer Bio, Inc. a partir del 29 de abril de 2024 es 9. Las puntuaciones principales son Auditoría: 7; Junta: 7; Derechos del accionista: 8; Compensación: 10.
